We are live on ! Find out more
ALNY icon

Alnylam Pharmaceuticals

524 hedge funds and large institutions have $29.1B invested in Alnylam Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 88 funds opening new positions, 191 increasing their positions, 165 reducing their positions, and 56 closing their positions.

New
Increased
Maintained
Reduced
Closed

78% more capital inflows, than outflows

Capital inflows: $1.9B | Capital outflows: $1.07B

57% more first-time investments, than exits

New positions opened: 88 | Existing positions closed: 56

17% more call options, than puts

Call options by funds: $703M | Put options by funds: $600M

16% more repeat investments, than reductions

Existing positions increased: 191 | Existing positions reduced: 165

5% more funds holding

Funds holding: 497 → 524 (+27)

3.68% more ownership

Funds ownership: 91.13% → 94.81% (+3.7%)

25% less funds holding in top 10

Funds holding in top 10: 8 → 6 (-2)

Holders
524
Holders Change
+27
Holders Change %
+5.43%
% of All Funds
7.54%
Holding in Top 10
6
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-25%
% of All Funds
0.09%
New
88
Increased
191
Reduced
165
Closed
56
Calls
$703​M
Puts
$600​M
Net Calls
+$103​M
Net Calls Change
-⁠$53.2​M

ALNY Hedge Fund Activity: Q2 2024 in Review

524 of the 6,945 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q2 2024, worth a combined $29.1B — up 70% from $17.2B a quarter earlier.

Buyers outnumbered sellers: 88 funds opened new ALNY positions and 56 closed out — a net gain of 32 holders — while 191 added to existing stakes and 165 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $347M. The largest seller was Wellington Management Group, cutting an estimated $158M.

  • 524 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q2 2024, up from 497 in Q1 2024.
  • Funds reported $29.1B of Alnylam Pharmaceuticals stock for Q2 2024, up 70% quarter-over-quarter.
  • 88 funds opened new Alnylam Pharmaceuticals positions in Q2 2024 and 56 closed out, a net change of +32 holders.
  • The largest Alnylam Pharmaceuticals buyer in Q2 2024 was Fidelity Investments, an estimated $347M added.
  • The largest Alnylam Pharmaceuticals seller in Q2 2024 was Wellington Management Group, an estimated $158M sold.

Based on aggregated 13F filings for Q2 2024.